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Vascular calcification - the deposition of excess mineral within the vessel wall - is now 25 
recognized as a complex, actively controlled process, principally mediated at the level of the 26 
vascular smooth muscle cell (VSMC). The extent of calcium deposition within the vessel wall 27 
can be used to predict the risk of adverse cardiac events (ACEs) (1). 28 
In the absence of vascular pathology, VSMCs exist in a quiescent state characterized by a set 29 
of contractile proteins such as CNN1 (calponin 1) and ACTA2 (alpha smooth muscle actin) 30 
which allow VSMCs to carry out their primary function, namely to provide structural support 31 
and to mediate vasoreactivity. In response to vascular injury/pathology, VSMCs can undergo 32 
a phenotypic transition towards a more synthetic phenotype. This change is characterized by 33 
downregulation of contractile proteins, increased proliferation and migration and enhanced 34 
extracellular matrix production. It is now widely thought that in disease, VSMCs form a 35 
heterogenous population with some VSMCs gaining an osteochondrogenic phenotype 36 
associated with osteogenic markers such as runt-related transcription factor 2 (RUNX2), type 37 
1 collagen (Col1A1) and enhanced response to bone morphogenetic protein-2 (BMP-2) (2). 38 
The accumulative effect of this phenotypic switch is a cell type much more prone to 39 
accumulating calcium deposits within the vessel wall; however, the molecular pathways that 40 
promote this event are still not well defined. 41 
In the study by Carracedo and colleagues (3) recently published in Cardiovascular Research, 42 
the authors investigated the role of the ChemR23 receptor in calcification of epigastric arteries 43 
derived from kidney transplant patients. In chronic kidney disease, vascular calcification is an 44 
independent predictor of cardiovascular morbidity and mortality and the primary inducer of 45 
vascular calcification in these patients is thought to be hyperphosphatemia (4). ChemR23 is a 46 
G-protein coupled receptor expressed on multiple cell types including VSMCs (5), and is 47 
upregulated during bone development. Chemerin was the first ChemR23 ligand discovered 48 
and induces pro-inflammatory properties via ChemR23 agonism (6). Subsequently, resolvin 49 
E1 (RvE1), an inflammatory resolving lipid mediator derived from the omega-3 fatty acid 50 
eicosapentaenoic acid (EPA), was also described in the literature as being a ligand for 51 
ChemR23 (7); however a direct interaction between RvE1 and ChemR23 is somewhat 52 
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controversial with other receptors such as  the  leukotriene B4 receptor BLT1 also a candidate 53 
for mediating the effects of RvE1 (8). In contrast to chemerin, the RvE1 interaction with 54 
ChemR23 has been reported to produce anti-inflammatory activity. RvE1 and other omega-3 55 
derived specialized proresolvin mediators (SPM) have shown promise in resolving 56 
inflammation in several diseases in humans (9). Moreover, data from animal models indicates 57 
that administration of RvE1 results in reduced atherosclerosis (10), and that ERV1/ChemR23 58 
signaling protects against atherosclerosis (11). However, the role of ChemR23 and RvE1 in 59 
VSMC calcification and osteogenesis has been unexplored until now. 60 
Gene expression analysis of patient arteries revealed ChemR23 to be an independent 61 
predictor of Col1A1. To obtain more insight into the effect of ChemR23 on VSMC phenotype, 62 
the authors next cultured VSMCs from ChemR23-/- and wild-type mice. Under cell culture 63 
conditions, VSMCs spontaneously de-differentiate yet this process was greatly attenuated in 64 
ChemR23-/- VSMCs. Furthermore, in response to elevated phosphate levels, calcification of 65 
cells was also attenuated in ChemR23-deficient VSMCs, as was activation of BMP-2 signaling, 66 
a known inducer of calcification in VSMCs under high phosphate conditions (2). Concomitant 67 
with reduced calcification was a reduction in pro-calcific RUNX2 and an increase in anti-calcific 68 
osteoprotegerin (OPG). To test the hypothesis in vivo, mice were injected with vitamin D3, 69 
which mimics phosphate induced calcification. ChemR23-/- mice had reduced calcification in 70 
the medial layer of the aortic root and carotid artery. These were accompanied by biochemical 71 
changes indicative of a less calcific, more contractile VSMC phenotype, despite ChemR23-/- 72 
mice displaying more pronounced hyperphosphatemia. This strengthens the view that the loss 73 
of ChemR23 is acting directly via VSMCs and not due to systemic metabolic changes, thus 74 
supporting the in vitro observations. RvE1 treated wild-type VSMCs showed reduced 75 
calcification and BMP-2 expression, effects not observed in ChemR23-/- VSMCs. The 76 
reduction in calcification was not associated with other changes in VSMC phenotype indicating 77 
RvE1 has calcification specific effects mediated by ChemR23. Finally, the authors introduced 78 
the C. elegans Fat 1 transgene into wild-type and ChemR23-/- mice. Fat 1 encodes a fatty acid 79 
desaturase that converts omega-6 to omega-3 fatty acids. The rationale being that enrichment 80 
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of EPA results in greater production of RvE1 as previously observed (12). In support of RvE1 81 
induced inhibition of ChemR23 mediated vascular calcification, the authors noted that 82 
ChemR23 dependent effects were attenuated in the presence of increased endogenous 83 
omega-3 production, potentially due to RvE1 inhibitory action (3). 84 
Derivatives of the omega-3 fatty acids EPA and docosahexaenoic acid (DHA) are thought to 85 
possess anti-inflammatory properties, acting to oppose the pro-inflammatory actions of cyclo- 86 
and lipoxygenase arachidonic acid products. The current work indicates that EPA derived 87 
RvE1 may also help in preventing the adverse phenotypic changes in VSMCs, such as 88 
accumulation of calcium, that run in parallel with vascular inflammation across a range of 89 
vascular pathologies. A multitude of studies looking at the cardioprotective effects of omega-90 
3 supplementation have failed to reach a consensus on whether there is a beneficial effect on 91 
CVD morbidity or mortality. Recently, attention has focused on the EPA content in omega-3 92 
formulations. A relatively low daily EPA dose (469 mg; 1-gram total omega-3) formulation 93 
proved ineffective in reducing ACEs in diabetic patients (13). A different trial involving more 94 
than 8000 participants across 11 countries employed a total daily dose of 4 g of a purified EPA 95 
ethyl ester formulation in patients at risk of CVD and with elevated triglycerides. Despite the 96 
concurrent use of statins, patients taking the EPA treatment had a 25% reduction in risk of 97 
ischemic events, including cardiovascular death, compared to those who received placebo 98 
(14). A similar trial (STRENGTH - Statin Residual Risk Reduction With Epanova in High 99 
Cardiovascular Risk Patients with Hypertriglyceridemia; ClinicalTrials.gov number, 100 
NCT02104817) is currently looking at the use of an EPA enriched omega-3 formulation 101 
(Epanova) in modifying ACEs in approximately 13000 statin treated patients. A positive 102 
outcome from both these trials would increase the therapeutic focus onto EPA and its 103 
derivatives. 104 
The understanding of endogenous SPM production as well as blood and tissue concentrations 105 
is an emerging area of research and the modulating role of these compounds in human 106 
disease is still unknown. Results between human subject studies to date are mixed regarding 107 
detection of circulating SPMs (15) and it is currently unclear what the dose-relationship is to 108 
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dietary intake of EPA. Translating in vivo based studies to human disease will require sensitive 109 
mass spectrometry profiling of SPMs in biological fluids from patient and control subjects. This 110 
could determine if circulating SPMs are biomarkers for CVD and may offer insight into the 111 
relationship between omega-3 intake and cardiovascular protection. Such personalized 112 
information based on SPM production could enable clinicians to better tailor omega-3/EPA 113 
doses in future trials and may shed light on why some patients show a therapeutic response 114 
to omega-3 intake and others do not. A key future goal would also be to determine if a failure 115 
to resolve inflammation is related to depleted local SPM levels and if administered EPA/DHA 116 
could reverse this trend. Furthermore, the identification of ligands and receptors such as RvE1 117 
and ChemR23 respectively could allow the use of more refined lipid preparations and also 118 
inform pharmacological approaches to design higher potency SPM analogues with a favorable 119 
anti-inflammatory/VSMC preserving profile. 120 
In summary, the current work highlights a novel role for the ChemR23 receptor in promoting 121 
VSMC differentiation towards an osteoblastic, synthetic phenotype and highlights RvE1 as an 122 
inhibitory ligand against ChemR23 mediated VSMC calcification, a hallmark feature of human 123 
vascular pathology. Given the current lack of treatments for reversing or halting VSMC 124 
calcification, the discovery that RvE1 as an inhibitor of this process is an important 125 
development and may contribute to the cardiovascular benefits of EPA. 126 
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Figure 1. ChemR23 as a mediator of VSMC dysfunction. RvE1 is derived from the Omega-189 
3 fatty acid, EPA (box). By acting as an inhibitory ligand on ChemR23, RvE1 causes a 190 
reduction in BMP-2 gene expression. BMP-2 promotes phosphate uptake via sodium-191 
dependent phosphate cotransporter PIT-1, and through this mechanism, enhances VSMC 192 
calcification. Therefore, the reduction in BMP-2 expression observed after RvE1 treatment in 193 
ChemR23+/+ cells likely results in reduced calcification due to reducing the accumulation of 194 
intracellular phosphate. This effect was mediated by ChemR23 since ChemR23-/- VSMCs did 195 
not show changes in calcification following RvE1 treatment. This study also reveals ChemR23 196 
to be a positive modulator of VSMC proliferation/differentiation. A possible candidate for 197 
ChemR23 activation is chemerin, a ChemR23 agonist. Activation of ChemR23 can induce 198 
aberrant VSMC phenotypic changes through enhancement of reactive oxygen species (ROS) 199 
and MAPK signaling. BLACK arrows show observed phenotypic changes and RED arrows 200 
show pathways inhibited after RvE1 treatment under elevated phosphate (PO43-) conditions. 201 
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